PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY MOLECULE TYPE
• Segmentation by molecule type
• Comparison by molecule type
• Biologicals – Market size and forecast 2017-2022
• Small molecules – Market size and forecast 2017-2022
Market opportunity by molecule type
PART 09: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 10: CUSTOMER LANDSCAPE
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Increasing patient support programs
• Strategic alliances
• Advanced technologies
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR LANDSCAPE
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• Biogen
• F. Hoffmann-La Roche
• Gilead
• Merck
PART 16: APPENDIX
• List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global NHL therapeutics market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global follicular lymphoma therapeutics market – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global follicular lymphoma therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition: Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Late stage pipeline molecules for the treatment of follicular lymphoma
Exhibit 20: Global follicular lymphoma therapeutics market – Market share by molecule type 2017-2022 (%)
Exhibit 21: Comparison by molecule type
Exhibit 22: Global follicular lymphoma therapeutics market by biologicals – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Global follicular lymphoma therapeutics market by biologicals – Year-over-year growth 2018-2022 (%)
Exhibit 24: Global follicular lymphoma therapeutics market by small molecules – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Global follicular lymphoma therapeutics market by small molecules – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by molecule type
Exhibit 27: Global follicular lymphoma therapeutics market – Market share by geography 2017-2022 (%)
Exhibit 28: Regional comparison
Exhibit 29: Follicular lymphoma therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Follicular lymphoma therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: Follicular lymphoma therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Follicular lymphoma therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: Follicular lymphoma therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 36: Follicular lymphoma therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Customer landscape
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bayer – Overview
Exhibit 46: Bayer – Business segments
Exhibit 47: Bayer – Organizational developments
Exhibit 48: Bayer – Geographic focus
Exhibit 49: Bayer – Segment focus
Exhibit 50: Bayer – Key offerings
Exhibit 51: Bayer – Key customers
Exhibit 52: Biogen – Overview
Exhibit 53: Biogen – Business segments
Exhibit 54: Biogen – Organizational developments
Exhibit 55: Biogen – Geographic focus
Exhibit 56: Biogen – Key offerings
Exhibit 57: Biogen – Key customers
Exhibit 58: F. Hoffmann-La Roche – Overview
Exhibit 59: F. Hoffmann-La Roche – Business segments
Exhibit 60: F. Hoffmann-La Roche – Organizational developments
Exhibit 61: F. Hoffmann-La Roche – Geographic focus
Exhibit 62: F. Hoffmann-La Roche – Segment focus
Exhibit 63: F. Hoffmann-La Roche – Key offerings
Exhibit 64: F. Hoffmann-La Roche – Key customers
Exhibit 65: Gilead – Overview
Exhibit 66: Gilead – Business segments
Exhibit 67: Gilead – Organizational developments
Exhibit 68: Gilead – Geographic focus
Exhibit 69: Gilead – Key offerings
Exhibit 70: Gilead – Key customers
Exhibit 71: Merck – Overview
Exhibit 72: Merck – Business segments
Exhibit 73: Merck – Organizational developments
Exhibit 74: Merck – Geographic focus
Exhibit 75: Merck – Segment focus
Exhibit 76: Merck – Key offerings
Exhibit 77: Merck – Key customers
【掲載企業】
Bayer, Biogen, F. Hoffmann-La Roche, Gilead, Merck